NCT06671340View on ClinicalTrials.gov

Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 2, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

January 31, 2026

Conditions
Diabetes MellitusPrediabetes / Type 2 Diabetes
Interventions
DRUG

Dorzagliatin

chronic treatment with dorzagliatin for 4 weeks (50mg twice daily or 75mg twice daily, oral)

Trial Locations (1)

Unknown

Phase 1 Clinical Trial Centre, Hong Kong

All Listed Sponsors
lead

Elaine Chow

OTHER